can tirzepatide cause acne Mounjaro Acne? Skin Changes Explained Acne Breakouts: What Your Skin

Por qu elegir Continental Hospitals

The GLP-1R/GIPR/GCGR triple agonist showed 22.1% weight loss at 48 weeks in Phase 2 and may set a higher efficacy ceiling in Phase 3 (TRIUMPH trials)

These effects lead to reduced caloric intake as patients consume less food, potentially resulting in lower energy levels

Injectable GLP-1s may be more suitable for: Patients aiming for the maximum possible reduction in body weight, those with co-existing conditions like heart disease or chronic kidney disease (due to specific FDA approvals for Ozempic), or those who prefer a simple weekly medication schedule

This work was supported by the Maurice Phyllis Paykel Trust of New Zealand (Grant number: 9102 3727459) awarded to Drs S Reddy, K Sun and Professor A Davidson

PlexusDx helps patients understand why progress slows and offers evidence-based strategies to sustain momentum